Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Minimally invasive glaucoma surgeries offer an alternative to glaucoma drops, which, in some cases, do not adequately lower IOP and show poor compliance.

The authors commented that the patient’s "age, relative acute onset, and lack of medical history make this an atypical ...

Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...

This week Bobbi Conner talks with Dr. Peter Tang about potential diabetes related vision changes. Dr. Tang is an ...

US FDA approves expanded label for ANI Pharma’s Iluvien to treat chronic non-infectious uveitis affecting the posterior segment of the eye: Baudette, Minnesota Monday, March 17, ...

Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...

The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...